Edwards Lifesciences (EW) has shared an update.
Edwards Lifesciences Corporation has announced its decision to acquire Innovalve Bio Medical Ltd., a company specializing in transcatheter mitral valve replacement, with the transaction expected to be completed by the end of 2024 for an approximate cash payment of $300 million. This forward-looking statement includes the company’s expectations about the acquisition’s completion but also cautions that such statements involve risks and uncertainties that could cause actual results to differ. Potential risks range from the possibility of the acquisition not closing as planned to various factors that could impact the company’s operations and stock price.
Learn more about EW stock on TipRanks’ Stock Analysis page.
